Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis.
Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis.
复制标题
DOI:
10.1016/j.ymthe.2005.02.019
复制
发表时间:
2005-07
期刊:
影响因子:
--
通讯作者:
Masaki Watanabe;M. Ebina;F. Orson;A. Nakamura;Kazuo Kubota;D. Koinuma;Kenichi Akiyama;M. Maemondo;S. Okouchi;M. Tahara;Kunio Matsumoto;Toshikazu Nakamura;T. Nukiwa
中科院分区:
文献类型:
--
作者:
Masaki Watanabe;M. Ebina;F. Orson;A. Nakamura;Kazuo Kubota;D. Koinuma;Kenichi Akiyama;M. Maemondo;S. Okouchi;M. Tahara;Kunio Matsumoto;Toshikazu Nakamura;T. Nukiwa
We examined therapeutic gene transfer of human hepatocyte growth factor (hHGF) to alveolar septa in mouse bleomycin-induced lung fibrosis using macroaggregated albumin-polyethylenimine complex (MAA-PEI). Intravenous administration of MAA-PEI along with 1 μg pCAG.hHGF to C57BL/6 mice increased the uptake of plasmids into alveolar capillary endothelial cells and epithelial cells, prolonged hHGF expression in the lung, and induced a level of hHGF expression equal to that seen with 10 μg of hHGF-expression plasmids alone. The exogenous source of hHGF gene expression increased the endogenous mouse HGF in the lungs and significantly decreased TNF-α, IL-6, and collagen synthesis after bleomycin injury. Because GFP-labeled bone marrow-derived stem cells after bleomycin injury were reduced in number by HGF, the primary mechanism of HGF is likely to be the prevention of apoptosis, as has been suggested byin vitroexperiments. This novel HGF gene transfer method to alveolar septa with nonstimulatory MAA-PEI conjugates may have promising clinical applications.